2022 World Conference on Lung Cancer (ePosters)-EP05.02-004. Could Fifty Percent Tumor Viability Be a Good Prognostic Factor?

Pdf Summary

This study examined the impact of tumor viability on overall survival in patients with non-small cell lung cancer after neoadjuvant therapy. A total of 105 patients who underwent lung surgery after neoadjuvant therapy were included in the study. It was found that 69.9% of the patients had a maximum tumor viability of 50% or less. <br /><br />The patients received different types of treatment, including chemotherapy (45.7%), chemoradiotherapy (38%), and chemoimmunotherapy (16.2%). Neoadjuvant treatment was chosen for 54.5% of the patients due to N2, while others were given treatment based on various locally advanced diseases. Adenocarcinoma was the most common diagnosis (51.5%).<br /><br />When survival analysis was performed based on tumor viability, it was observed that the 2-year and 5-year survivals were better in the group with 50% or less tumor viability, although the difference was not statistically significant. The 2-year survival rate was 85% in the group with viability below 50% compared to 75.7% in the other group. Similarly, the 5-year survival rate was 78.9% in favor of the group with lower tumor viability compared to 56.7% in the other group.<br /><br />Although a tumor viability of 10% or less is known to be a good prognostic factor in lung cancers after neoadjuvant therapy, this study suggests that viability up to 50% may also be a relatively good prognostic factor. However, further multicenter studies are needed to confirm these findings in more homogeneous patient groups.

Asset Subtitle

Ezgi Cesur

Meta Tag

Speaker Ezgi Cesur

Topic Locally Advanced Non-small Cell Lung Cancer - Neoadjuvant and Adjuvant Therapy

Keywords

tumor viability

overall survival

non-small cell lung cancer

neoadjuvant therapy

lung surgery

chemotherapy

chemoradiotherapy

chemoimmunotherapy

N2

locally advanced diseases